A case for targeting Th17 cells and IL-17A in SARS-CoV-2 infections
M Orlov, PL Wander, ED Morrell… - The Journal of …, 2020 - journals.aai.org
Abstract SARS-CoV-2, the virus causing COVID-19, has infected millions and has caused
hundreds of thousands of fatalities. Risk factors for critical illness from SARS-CoV-2 infection …
hundreds of thousands of fatalities. Risk factors for critical illness from SARS-CoV-2 infection …
Inflammatory cytokine: IL-17A signaling pathway in patients present with COVID-19 and current treatment strategy
T Shibabaw - Journal of inflammation research, 2020 - Taylor & Francis
Abstract Coronavirus disease 2019 (COVID-19) is a globally communicable public health
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV-2) …
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV-2) …
The role of Th17 response in COVID-19
D Martonik, A Parfieniuk-Kowerda, M Rogalska… - Cells, 2021 - mdpi.com
COVID-19 is an acute infectious disease of the respiratory system caused by infection with
the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus 2). Transmission …
the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus 2). Transmission …
Neutrophils mediate Th17 promotion in COVID-19 patients
Z Parackova, M Bloomfield, A Klocperk… - Journal of Leucocyte …, 2021 - academic.oup.com
From the beginning of 2020, an urgent need to understand the pathophysiology of SARS-
CoV-2 disease (COVID-19), much of which is due to dysbalanced immune responses …
CoV-2 disease (COVID-19), much of which is due to dysbalanced immune responses …
May IL-17 have a role in COVID-19 infection?
M Megna, M Napolitano, G Fabbrocini - Medical hypotheses, 2020 - ncbi.nlm.nih.gov
SARS-Corona-Virus-2 related disease (COVID-19) which started in Wuhan, China on
December 2019, is spreading rapidly throughout the world [1]. COVID-19 clinical spectrum is …
December 2019, is spreading rapidly throughout the world [1]. COVID-19 clinical spectrum is …
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia
S De Biasi, M Meschiari, L Gibellini, C Bellinazzi… - Nature …, 2020 - nature.com
The immune system of patients infected by SARS-CoV-2 is severely impaired. Detailed
investigation of T cells and cytokine production in patients affected by COVID-19 pneumonia …
investigation of T cells and cytokine production in patients affected by COVID-19 pneumonia …
[HTML][HTML] TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
COVID-19 emerges as a pandemic disease with high mortality. Development of effective
prevention and treatment is an urgent need. We reviewed TH17 responses in patients with …
prevention and treatment is an urgent need. We reviewed TH17 responses in patients with …
[HTML][HTML] Interleukin-17A (IL-17A): A silent amplifier of COVID-19
One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia
followed by systemic inflammation. Emerging evidence has identified a potential link …
followed by systemic inflammation. Emerging evidence has identified a potential link …
COVID‐19 immunopathology with emphasis on Th17 response and cell‐based immunomodulation therapy: potential targets and challenges
A Pourgholaminejad… - Scandinavian Journal …, 2022 - Wiley Online Library
The role of the immune system against coronavirus disease 2019 (COVID‐19) is unknown in
many aspects, and the protective or pathologic mechanisms of the immune response are …
many aspects, and the protective or pathologic mechanisms of the immune response are …
COVID-19: a case for inhibiting IL-17?
IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …